Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity

Clinical Cancer Research

Volumn 7, Issue 12, 2001, Pages 4156-4163

  Tortora, Giampaolo ^a   Caputo, Rosa ^a   Damiano, Vincenzo ^a   Melisi, Davide ^a   Veneziani, Bianca M ^a   Bianco, A Raffaele ^a   Ciardiello, Fortunato ^a   Fontanini, Gabriella ^b   Zunino, Franco ^c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; ORTATAXEL; TAXANE DERIVATIVE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL TRANSFORMATION; COLON CANCER; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL DIVISION; CELL SURVIVAL; COLONIC NEOPLASMS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; LYMPHOKINES; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; OVARIAN NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035674731     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. cAMP-dependent protein kinase: Role in normal and malignant growth
2. Targeting of epidermal growth factor receptor and protein kinase A: Molecular basis and therapeutic applications
3. The RIα subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor
4. Downregulation of RIα subunit of the cAMP-dependent protein kinase induces growth inhibition of human mammary epithelial cells transformed by c-Ha-ras and c-erbB2 protooncogenes
5. A single-injection protein kinase A-directed antisense treatment to inhibit tumour growth
6. Antisense therapeutics
7. Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A
8. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM 231) targeting the type I protein kinase A by 2-hour infusions in patients with refractory solid tumors
9. Antitumor activity and pharmacokinetics of a mixed-backbone oligonucleotide targeted to the RIα subunit of protein kinase A following oral administration
10. Oral antisense targeting protein kinase A cooperates with Taxol and inhibits tumor growth, angiogenesis, and growth factors production
11. Epidermal growth factor-related peptides and their receptors in human malignancies
12. The epidermal growth factor receptor and its inhibition in cancer therapy
13. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an EGFR-selective tyrosine kinase inhibitor
14. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A
15. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor receptor antibody on human breast cancer cell growth
16. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts
17. Anti-proliferative activity of a new class of taxanes (14βhydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells
18. Oral efficacy and bioavailability of a novel taxane
19. IDN5109, a taxane with oral bioavailability and potent antitumor activity
20. Large-scale synthesis, purification, and analysis of oligodeoxynucleotide phosphorothioates
21. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors
22. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: Amphiregulin and microvessel count are independent prognostic indicators of survival
23. Tumor development under angiogenic signaling: A dynamical theory of tumor growth, treatment response, and postvascular dormancy
24. Neutralizing antibodies against epidermal growth factor and erbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo
25. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
26. TGFα and angiogenesis
27. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiforme pathophysiology
28. Transforming growth factor α-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP2-dependent DNA binding and transactivation
29. Antiangiogenic and antitumor activity of anti-EGFR C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells
30. Inhibition of growth factors production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
31. 8-Chloro-cAMP inhibits autocrine and angiogenic growth factors production in human colorectal and breast cancer
32. The microtubule-affecting drug paclitaxel has antiangiogenic activity
33. Type I protein kinase A is localized to interphase microtubules and strongly associated with the mitotic spindle
34. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
35. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
36. On receptor inhibitors and chemotherapy